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Abstract IgG4-relateddisease(IgG4RD)isanovelclinical
disease entity characterized by elevated serum IgG4 concen-
tration and tumefaction or tissue inﬁltration by IgG4-positive
plasma cells. IgG4RD may be present in a certain proportion
of patients with a wide variety of diseases, including Miku-
licz’s disease, autoimmune pancreatitis, hypophysitis, Riedel
thyroiditis, interstitial pneumonitis, interstitial nephritis,
prostatitis, lymphadenopathy, retroperitoneal ﬁbrosis,
inﬂammatory aortic aneurysm, and inﬂammatory pseudotu-
mor. Although IgG4RD forms a distinct, clinically indepen-
dent disease category and is attracting strong attention as a
new clinical entity, manyquestionsandproblemsstill remain
tobeelucidated,includingitspathogenesis,theestablishment
of diagnostic criteria, and the role of IgG4. Here we describe
the concept of IgG4RD and up-to-date information on this
emerging disease entity.
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Abbreviations
IgG4RD IgG4-related disease
MD Mikulicz’s disease
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Japan
LPSP Lymphoplasmacytic sclerosing
pancreatitis
AIP Autoimmune pancreatitis
FMF Familial multifocal ﬁbrosclerosis
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Introduction
In 1892, Dr. Johann von Mikulicz, also known as Jan
Mikulicz-Radecki, published a paper describing a patient
with symmetrical swelling of the lachrymal, parotid, and
submandibular glands, with massive inﬁltration of these
glands by mononuclear cells [1]. Following reports
describing similar patients, this condition was called
Mikulicz’s disease (MD). In contrast, patients with similar
symptoms, but with diseases such as leukemia, malignant
lymphoma, and sarcoidosis, were reported to have
Mikulicz’s syndrome [2]. In 1930, Dr. Henrik Sjo ¨gren, an
ophthalmologist, published a paper describing a woman
with rheumatoid arthritis accompanied by keratoconjunc-
tivitis sicca and severe swelling of the parotid glands, a
condition that has been recognized as Sjo ¨gren’s syndrome
(SS) [3]. In 1953, Morgan and Castleman examined 18
patients with MD and concluded that this condition is one
manifestation of SS [4]. Since then, MD has attracted very
little interest in western countries. In Japan, however, there
have been many patients with MD, such that differences
between MD and SS have been clariﬁed [5–7]. For
example, their gender distribution is quite different, in that
MD occurs in both men and women, whereas SS occurs
mainly in women. Second, patients with MD have rela-
tively mild xerostomia and xerophthalmia, despite signiﬁ-
cant enlargement of their lachrymal and salivary glands.
Further, MD is accompanied by more complications, such
as autoimmune pancreatitis (AIP). Patients with MD show
a better response to glucocorticoid therapy than patients
with SS. Finally, it has become clear that MD is related to
elevated serum IgG4 concentrations and inﬁltration of
IgG4-positive cells [5–9].
Following the description of a patient with chronic
pancreatitis due to an autoimmune mechanism [10], lym-
phoplasmacytic sclerosing pancreatitis (LPSP) was found
to be a characteristic histopathological ﬁnding in patients
with AIP [11]. These ﬁndings led to the concept of AIP,
which has characteristics similar to those of other auto-
immune diseases, such as hypergammaglobulinemia, the
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123presence of various autoantibodies, lymphocytic inﬁltration
into pancreatic tissue, and good responsiveness to steroids
[12]. Following a report showing elevated serum IgG4 con-
centrations in patients with AIP [13], the pancreatic research
team of the Ministry of Health, Labor and Welfare Japan
(MHLW Japan) showed that AIP was related to IgG4 [14].
IgG4-positive plasma cell inﬁltration has also been
observed in patients with other conditions, including retro-
peritoneal and mediastinal ﬁbrosis [15, 16], inﬂammatory
pseudotumor of the lung and liver [17], Ku ¨ttner tumor [18],
and interstitial nephritis [19], indicating that these diseases
andconditionscollectivelyconstituteanewdiseaseconcept,
IgG4-related disease (Fig. 1). These ﬁndings have led to the
organization of two study groups by MHLW Japan to ana-
lyze the condition of IgG4-related disease. These groups
consistofdoctorsandresearchersinvariousﬁelds,including
rheumatology, hematology, gastroenterology, nephrology,
pulmonology, ophthalmology, odontology, pathology, sta-
tistics, and basic and molecular immunology, from all over
Japan.Oneofthesegroups,chairedbyProfessorUmeharaof
Kanazawa Medical University, is seeking to establish diag-
nostic criteria for IgG4-related multi-organ lymphoprolif-
erative syndrome (IgG4-MOLPS), whereas the second
group, chaired by Professor Okazaki of Kasai Medical
University, is seeking to understand the etiology and path-
ogenesis of IgG4-related systemic disease.
Uniﬁcation of different nomenclatures for IgG4-related
disease (IgG4RD)
The concept of IgG4RD arose when elevated serum IgG4
concentrations were ﬁrst reportedin patients with sclerosing
pancreatitis [13]. Autoimmune pancreatitis (AIP) is also
associated with a variety of extrapancreatic lesions, includ-
ing sclerosing cholangitis, sclerosing sialadenitis, and dac-
ryoadenitis, resulting in the concept of IgG4-related
systemic disease [20], also called IgG4-related autoimmune
disease [21] or IgG4-related sclerosing disease [15]. The
ﬁnding of elevated serum IgG4 and IgG4-positive plasma
cell inﬁltration in MD suggested that MD was a systemic
disease, which was called systemic IgG4 plasmacytic syn-
drome (SIPS) [22]. Further, a comparison of patients with
MDandthosewithtypicalSSresultedintheformulationofa
new clinical entity, IgG4?MOLPS [23]. Although many
reportsfromJapanandothercountrieshave described IgG4-
related conditions under different names (Table 1), these
may refer to the same condition, familial multifocal ﬁbro-
sclerosis (FMF). Indeed, retroperitoneal ﬁbrosis (RPF),
mediastinal ﬁbrosis, sclerosing cholangitis, Riedel’s thy-
roiditis, and pseudotumor of the orbit may all be different
manifestations of a single disease [24].
The name ‘‘IgG4-related sclerosing disease’’ is mainly
based on the swellingof ﬁbrous organs, such as the pancreas
and retroperitoneum, whereas ‘‘SIPS’’ and ‘‘IgG4?MOL-
PS’’ are based on lymphoplasmacyticproliferation in glands
and swollen lymph nodes without ﬁbrosis. Although many
patients with this condition (i.e., IgG4-related sclerosing
disease, etc.) have lesions in several organs, either syn-
chronously or metachronously, other patients show
involvementofonlyasingleorgan.Atthispoint,itisunclear
whether the pathogenetic mechanism of this disease is sys-
temic or whether it consists of manifestations in individual
organs. In addition, several reports have described patients
with IgG4-associated conditions concomitant with malig-
nant tumors such as pancreatic [25, 26] and salivary [27]
carcinomas, and ocular adnexal lymphoma [28]. Therefore,
using the term ‘systemic’ may lead to an incorrect diagnosis
of an IgG4-related condition in a patient with malignant
Table 1 Nomenclatures of IgG-related conditions
IgG4-related autoimmune disease Kamisawa
[21]
IgG4-associated multifocal systemic ﬁbrosis van der Vliet
[76]
IgG4-related systemic disease Kamisawa
[20]
IgG4-related sclerosing disease Kamisawa
[15]
Hyper-IgG4 disease Neild [59]
IgG4-related disease (IgG4-RD) Zen [77]
Systemic IgG4 plasmacytic syndrome (SIPS) Yamamoto
[22]
IgG4-related multi-organ lymphoproliferative
syndrome (IgG4-MOLPS)
Masaki [29]
IgG4-associated disease Geyer [78]
Fig. 1 IgG4-related conditions. Many diseases have been reported to
be IgG4-related
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123tumorsinotherorgans.Basedonthesereasons,themembers
of the two MHLW Japan research teams agreed, at their
second meeting in Kanazawa on February 11, 2010, to use
the term ‘‘IgG4-related disease (IgG4RD)’’.
General concept of IgG4RD
After the uniﬁcation of the disease name as IgG4RD, both
MHLW Japan research teams have sought to determine its
pathogenesis and to formulate diagnostic criteria. The two
teams reached a consensus that IgG4RD can occur in
various organs, including the central nervous system, sal-
ivary glands, thyroid gland, lungs, pancreas, biliary duct,
liver, gastrointestinal tract, kidneys, prostate gland, retro-
peritoneum, and lymph nodes, but that clinical symptoms
depend on the location of the lesion. IgG4RD mainly
affects middle-aged to elderly men. Its clinical symptoms
are relatively mild, and the condition usually comes to
clinical attention due to organ swelling or damage. Many
patients with IgG4RD are treated effectively by steroid
therapy. Although the inﬁltration of IgG4-positive cells and
increased serum concentrations of IgG4 are characteristic
of IgG4RD, the severity of ﬁbrosis is dependent on the
individual organs involved. For example, storiform ﬁbrosis
and obliterative phlebitis are characteristic of pancreatic,
biliary tract, and retroperitoneal lesions, but are very sel-
dom found in salivary glands or lymph nodes (Fig. 2).
Prevalence of IgG4RD
It is difﬁcult to ascertain the number of patients with
IgG4RD because its diagnostic criteria have not yet been
established, the awareness of this disease is low, and its
symptoms vary. An attempt was made to estimate the
number of individuals with IgG4RD throughout Japan by
using as an example Ishikawa Prefecture, which has a
population of 1.14 million people with little population
inﬂow/outﬂow (Fig. 3). In Ishikawa Prefecture, there are
Fig. 2 Histopathology of IgG4-related disease (IgG4RD). IgG4RD is
characterized histopathologically by the inﬁltration of IgG4-positive
plasmacellsandﬁbrosis.However,theseverityofﬁbrosisisdependent
on the individual organs involved. For example, storiform ﬁbrosis and
obliterative phlebitis are characteristic of retroperitoneal lesions, but
are very seldom observed in salivary glands (940)
Fig. 3 Prevalence of patients with IgG4RD. An attempt was made to
estimate the number of individuals with IgG4RD throughout Japan by
using as an example Ishikawa Prefecture (population 1.14 million
people) with little population inﬂow/outﬂow. If all new patients with
IgG4RD visit Kanazawa Medical University Hospital (KMU)o r
Kanazawa University Hospital (KUH), the incidence of this disease
throughout Japan would be 0.28–1.08/100,000 population, with
336–1,300 patients newly diagnosed per year. If life expectancy after
diagnosis is 20 years, then approximately 6,700–26,000 patients in
Japan would have developed IgG4RD over the past 20 years. The
numbers in the table represent the numbers of patients who visited
KMU or KUH each year
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123two University Hospitals, Kanazawa Medical University
Hospital(KMU)andKanazawaUniversityHospital(KUH).
Assumingthat new patients with IgG4RDwould visit oneof
thesetwohospitals,itwasestimatedthattheincidenceofthis
disease throughout Japan would be 0.28–1.08/100,000
population, with 336–1,300 patients newly diagnosed per
year.BecausethemedianageofonsetofIgG4RDis58 years
and the clinical symptoms are relatively mild, with slow
progression and good response to steroid therapy, life
expectancy after diagnosis was estimated at 20 years. Thus,
an estimated 6,700–26,000 individuals in Japan would have
developed IgG4RD over the past 20 years.
Clinicopathological features of IgG4RD
Differences between IgG4-related MD and Sjo ¨gren’s
syndrome
Since elevated serum IgG4 was ﬁrst reported in patients
with MD [6], the members of the Japanese Society of
Sjo ¨gren’s Syndrome have assessed the clinical symptoms,
laboratory ﬁndings, and detailed histopathology in patients
with MD (characterized by symmetrical swelling of the
lachrymal, submandibular, and parotid glands), nationwide,
since 2004. Some patients did not show typical symptoms
of MD such as swelling of the lachrymal, parotid, or sub-
mandibular glands but showed elevated serum IgG4 and
other indices indicative of MD according to the criteria for
the diagnosis of IgG4-related MD shown in Table 2 [8].
Sixty-four patients with MD or elevated serum IgG4
([135 mg/dl) and characteristic histological ﬁndings were
initially diagnosed with IgG4RD (formerly called
IgG4?MOLPS) based on proposed guidelines for the
diagnosis of IgG4RD (Table 3). A comparison of patients
with IgG4RD and those with typical SS showed: (1)
compared with SS patients, fewer patients with IgG4RD
had symptoms of xerophthalmia, xerostomia, or arthralgia,
whereas many had coexisting AIP, interstitial nephritis,
allergic rhinitis, and/or bronchial asthma (Fig. 4a); (2)
most patients with IgG4RD were negative for anti-SS-A
and anti-SS-B antibodies, as well as for rheumatoid factor
(RF) and anti-nuclear antibody (ANA) (Fig. 4b); (3) serum
IgG4 and IgE concentrations were signiﬁcantly higher in
IgG4RD than in SS patients (Fig. 4c); and (4) steroid
therapy was extremely effective in patients with IgG4RD
but had limited effect in patients with SS [29].
The histopathological features of IgG4RD are unique,
though both IgG4RD and SS show marked lymphocytic
inﬁltration. IgG4RD is characterized by the formation of
lymphoid follicles but lower levels of lymphocytic inﬁl-
tration into the salivary ducts, such that their structure
remains intact (Fig. 5a). Therefore, the absence of
Table 3 Guidelines for diagnosis of IgG4RD (proposed by the
Research Program for Intractable Disease Ministry of Health, Labor
and Welfare Japan, G4 team)
Clinical features highly suggestive of IgG4RD
1. Symmetrical swelling of lachrymal, parotid, or submandibular
glands
2. Autoimmune pancreatitis
3. Inﬂammatory pseudotumor
4. Retroperitoneal ﬁbrosis
5. Suspicion of Castleman’s disease
Laboratory data highly suggestive of IgG4RD
1. Serum IgG4[135 mg/dl
2. IgG4? cells/IgG? cells[40% in biopsy
Clinical features suggestive of IgG4RD
1. Unilateral swelling of at least one lachrymal, parotid, or
submandibular gland
2. Orbital pseudotumor
3. Sclerosing cholangitis
4. Prostatitis
5. Hypertrophic pachymeningitis
6. Interstitial pneumonitis
7. Interstitial nephritis
8. Thyroiditis/hypo-function of thyroid
9. Hypophysitis
10. Inﬂammatory aneurysm
Laboratory data suggestive of IgG4RD
1. Hypergammaglobulinemia of unknown origin
2. Hypocomplementemia or existence of immune complex
3. Increase of IgE or eosinophils
4. Tumefactive lesions or lymph node swelling detected by
gallium scan or ﬂuoro-D-glucose positron emission tomography
(FDG-PET)
Table 2 Diagnostic criteria of IgG4? Mikulicz’s disease [8]
(approved by the Japanese Society for Sjo ¨gren’s Syndrome 2008)
1. Symmetrical swelling of at least 2 pairs of lachrymal, parotid, or
submandibular glands for at least 3 months
AND
2. Elevated serum IgG4 ([135 mg/dl)
OR
3. Histopathological features including lymphocyte and IgG4?
plasma cell inﬁltration (IgG4? plasma cells/IgG? plasma cells
[50%) with typical tissue ﬁbrosis or sclerosis
Differential diagnosis is necessary to distinguish IgG4?
Mikulicz’s disease from other distinct disorders, including
sarcoidosis, Castleman’s disease, Wegener’s granulomatosis,
lymphoma, and cancer. The diagnostic criteria for Sjo ¨gren’s
syndrome (SS) may also include some patients with IgG4?
Mikulicz’s disease; however, the clinicopathological conditions
of patients with typical SS and IgG4? Mikulicz’s disease are
different
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123lymphoepithelial lesions in patients with IgG4RD, in
contrast to SS, may explain the lower rate of dryness in the
former, despite the marked swelling of lachrymal and
salivary glands. The most important difference between
IgG4RD and SS is that the former is characterized by
marked inﬁltration of IgG4-positive plasma cells, with a
Fig. 4 Comparison of clinical
symptoms and laboratory
ﬁndings in IgG4RD and typical
Sjo ¨gren’s syndrome (SS)[ 29].
a Clinical symptoms,
b immunological ﬁndings, and
c subclasses of
immunoglobulins and IgG
observed in patients with
IgG4RD (n = 61) and typical
SS (n = 31). Data are expressed
as percentages. P values are for
comparisons of IgG4RD with
typical SS. Patients with typical
SS fulﬁlled both Japanese and
European SS criteria and were
positive for both anti-SSA/Ro
and anti-SSB/La antibodies
6 Mod Rheumatol (2012) 22:1–14
123ratio of IgG4-positive to IgG-positive cells of [40%, a
ﬁnding almost never seen in patients with SS (Fig. 5b).
Moreover, most patients with IgG4RD show polyclonal
B-cell proliferation, with equal staining for immunoglob-
ulin j- and k-chains (Fig. 5c). Thus, despite their similar-
ities in organ involvement, IgG4-MD and SS are quite
different conditions, with distinct clinical and pathological
characteristics [7–9, 22, 29–31].
IgG4-related Ku ¨ttner tumor
Ku ¨ttner tumor, a unilateral sclerosing sialadenitis, is an
IgG4RD [18]. A common feature of MD and Ku ¨ttner tumor
is that both manifest sialadenitis, as in IgG4RD. Histo-
logically, Ku ¨ttner tumors are very severe ﬁbrous sclerotic
lesions containing IgG4-positive plasma cells [32]. In
contrast, ﬁbrosis tends to be less severe in MD, although
ﬁbrosis in MD is frequently not examined extensively,
because MD is generally diagnosed by the biopsy of minor
labial salivary glands. Therefore, at present, it is difﬁcult to
set a strict boundary between MD and Ku ¨ttner tumor.
IgG4-related autoimmune pancreatitis
(IgG4-related AIP)
Recent studies have suggested that AIP manifests as two
distinct subtypes, called types 1 and 2 (Table 4)[ 33].
Clinically, type 1 AIP seems to be the pancreatic mani-
festation of IgG4RD, characterized by: (1) mild abdominal
symptoms, usually without acute attacks of pancreatitis; (2)
occasional occurrence of obstructive jaundice; (3) increased
serum gammaglobulin, IgG, and/or IgG4 concentrations;
(4) presence of autoantibodies; (5) diffuse enlargement
of the pancreas with a capsule-like low-density rim; (6)
Fig. 5 Histopathological
ﬁndings of minor labial salivary
gland biopsies in patients with
IgG4RD and typical SS.
a Massive inﬁltration of
lymphocytes and plasma cells
was observed in patients with
IgG4RD and those with typical
SS (9200). IgG4RD, however,
was characterized by lymphoid
follicle formation but ducts
were intact without lymphocytic
inﬁltration. H&E staining.
b IgG4RD showed scattered
IgG4? plasma cells in the
periphery of the follicles
(9200), whereas typical SS
showed few or no IgG4? cells.
IgG4 immunostaining.
c Staining for immunoglobulin
j- and k-chains (9200)
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123irregular narrowing of the pancreatic duct (sclerosing pan-
creatitis on endoscopic retrograde cholangiopancreatogra-
phy [ERCP] images); (7) lymphocyte and IgG4-positive
plasmacyte inﬁltration and ﬁbrosis, and obliterative phlebi-
tis; (8) occasional association with extrapancreatic lesions,
such as sclerosing cholangitis similar to primary sclerosing
cholangitis (PSC), sclerosing cholecystitis, sclerosing sialo-
adenitis, RPF, interstitial renal tubular disorders, enlarged
celiac and hilar lymph nodes, chronic thyroiditis, and
pseudotumor of the pancreas, liver, or lung; and (9)
responsiveness to steroid therapy. Older males with IgG-
related AIP often have obstructive jaundice, with both
pancreatic and extrapancreatic manifestations responding to
steroid therapy [12–15, 21, 33, 34].
Histological examination by American and European
pathologists of the resected pancreases of patients with
chronic non-alcoholic pancreatitis revealed another histo-
pathological pattern, called idiopathic duct-centric pan-
creatitis (IDCP) or AIP with granulocytic epithelial lesions
(GELs), later called type 2 AIP [35, 36]. Type 2 AIP is
characterized primarily by these GELs, often accompanied
by destruction and obliteration of the pancreatic duct [36].
Patients with type 2 AIP show swelling of the pancreas, but
no or very few IgG4-positive plasma cells. Type 2 AIP has
different clinicopathological features than type 1 AIP. Type
2 AIP shows no elevations in serum IgG4 or IgG, no
autoantibodies, and no involvement of other organs, except
for inﬂammatory bowel disease. Inﬂammatory bowel dis-
ease has been observed in approximately 30% of patients
with type 2 AIP. Although type 1, or IgG4-related, AIP
(LPSP type) often occurs in older men and is accompanied
by a variety of extrapancreatic lesions, type 2, or neutro-
phil-related pancreatitis (IDCP/GEL type), has no gender
bias, younger age at onset (often \40 years), and is fre-
quently associated with inﬂammatory bowel disease. Thus,
after a worldwide debate over the diagnostic criteria for
AIP, IgG4-related pancreatitis has been deﬁned as type 1
(LPSP type) and neutrophil-related pancreatitis has been
deﬁned as type 2 (IDCP/GEL type) [34].
IgG4-related sclerosing cholangitis (IgG4-related SC)
Extrapancreatic bile duct lesions are frequently associated
with AIP. For example, 73% of patients with AIP have
shown wall thickening or sclerosing changes in extrapan-
creatic bile ducts on endoscopic ultrasonography (EUS)
and intraductal ultrasonography (IDUS), though only 26%
of patients with AIP demonstrated sclerosing changes by
ERCP [37]. However, many individuals without AIP have
shown IgG4-related SC with isolated biliary tract
involvement [38, 39]. In IgG4-related SC, stenosis is usu-
ally observed in the lower part of the common bile duct.
The cholangiographic appearance of stenosis in the intra-
hepatic or hilar hepatic bile duct is very similar to that
observed in PSC [40], a progressive disease of unknown
etiology that ultimately results in liver cirrhosis. IgG4-
related SC is associated with older age, male predomi-
nance, obstructive jaundice, weight loss, and abdominal
discomfort [40]. Although steroid therapy has shown
mixed results in patients with PSC, IgG4-related SC
Table 4 Subtypes of
autoimmune pancreatitis (AIP)
[33]
GEL, granulocyte epithelial
lesion; LPSP,
lymphoplasmacytic sclerosing
pancreatitis; IDCP, idiopathic
duct-centric chronic
pancreatitis; NS, not signiﬁcant
Subtype of AIP other nomenclatures Type 1 AIP without GEL
IgG4-related, LPSP
Type 2 AIP with GEL
IgG4-unrelated IDCP
Prevalence Asia[USA, Europe Europe[USA[Asia
Age High age Younger
Gender Male  female Male = female (NS)
Symptoms Often obstructive jaundice Often obstructive jaundice
Jaundice Rare abdominal pain Abdominal pain like acute pancreatitis
Pancreas images Swelling/diffuse Swelling/diffuse
Segmental/focal Segmental/focal
Mass-forming Mass-forming
Serology High serum IgG Normal IgG
High serum IgG4 Normal IgG4
Auto antibodies (?) Auto antibodies (-)
Other organ involvement (OOI) Sclerosing cholangitis Unrelated to OOI
Sclerosing sialadenitis
Retroperitoneal ﬁbrosis
Other characteristics
Ulcerative colitis Rare Often
Steroid response Responsive Responsive
Relapse High rate Rare
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123responds dramatically to steroid therapy, as does IgG4RD
[41]. The histopathological features of IgG4-related SC are
similar to those of AIP and include diffuse plasmacytic
inﬁltration, marked interstitial ﬁbrosis with a focal stori-
form-like pattern, and obliterative phlebitis.
IgG4-related kidney disease (IgG4-related KD)
The kidney is a frequent target organ in IgG4RD, with
tubulointerstitial nephritis (TIN) and ﬁbrosis and abundant
IgG4-positive plasma cell inﬁltration being diagnostically
important histopathological features of this disease [42–
44]. Recently, the clinicopathological features of 23
patients with IgG4-related TIN were reported to be quite
uniform and similar to those observed in patients with
IgG4-AIP, including high serum concentrations of IgG4
and IgE, hypocomplementemia, and TIN with inﬁltration
of large numbers of IgG4-positive plasma cells plus ﬁbrosis
[45].
Kidney diseases in IgG4RD include conditions other
than renal parenchymal lesions, such as hydronephrosis
associated with RPF and tumors of the renal pelvis and
urethra. However, IgG4-related TIN is considered to be
representative of IgG4 renal parenchymal lesions [19].
Compared with other types of interstitial nephritis, IgG4-
related TIN is often associated with extrarenal lesions, such
as pancreatitis, sialadenitis, and lymphadenitis, and a high
incidence of hypocomplementemia [46]. Imaging often
shows heterogeneous shadows in the kidneys, such as a
mass or multiple nodules (ﬁndings that are not observed in
other types of interstitial nephritis). Histopathologically,
the renal tubulointerstitium shows the inﬁltration of many
lymphocytes and plasmacytes, as well as ﬁbrosis, and IgG4
immunostaining shows a number of IgG4-positive plasma
cells [47]. Although many studies have found no signiﬁcant
changes in the glomeruli, others have reported an associ-
ation with glomerular lesions, including membranous
nephropathy [46]. In the near future, the Japanese Kidney
Society expects to develop diagnostic criteria for IgG4-
related KD.
IgG4-related pulmonary diseases (IgG4-related PD)
IgG4-related PD has been described as inﬂammatory
pseudotumor, interstitial pneumonitis, organizing pneu-
monia, and lymphomatoid granulomatosis [48]. Most
(81%) patients with IgG4-related PD have been reported to
be men, with a median age at diagnosis of 69 years [48],
features similar to those of IgG4RD. Some patients present
initially with respiratory symptoms, such as dry cough or
dyspnea, whereas 75% of patients are asymptomatic and
the disease is found incidentally by abnormal shadows on
chest X-rays. Although IgG4-related PD is associated with
a variety of radiologic abnormalities [49], diffuse lym-
phoplasmacytic inﬁltration has been observed in all lesions,
with irregular ﬁbrosis and obliterative vascular changes
being more common in solid areas [48]. Hilar and pan-
creatic accumulation of gallium-67 has been reported as
characteristic of the active stage of AIP when serum IgG4
concentrations are high [50].
Radiographically, IgG4-related PD can be divided into
two types, inﬂammatory pseudotumors and interstitial
pneumonitis. Inﬂammatory pseudotumors have been
described as nodular or mass lesions, or inﬁltration, and are
characterized by radiating reticular shadows surrounding
the tumor. Interstitial pneumonitis presents in most patients
with reticular shadows, ground-glass opacity, and intersti-
tial ﬁbrosis in both lower lung ﬁelds [17].
Histopathologically, inﬂammatory pseudotumor is a
plasma cell granuloma, with inﬁltration mainly by plasma
cells and lymphocytes, irregular ﬁbrosis, lymphoid follicle
formation, ﬁndings of interstitial pneumonitis at the
periphery of the nodule, obliterating phlebitis and arteritis,
and eosinophilic inﬁltration [17]. Interstitial pneumonitis is
characterized by thickening of the alveolar septa due to
inﬁltration by plasma cells and lymphocytes, and by diffuse
ﬁbrosis. Histopathologically, interstitial pneumonitis often
shows a pattern previously classiﬁed as non-speciﬁc
interstitial pneumonia (NSIP) [51]. The diagnostic criteria
for IgG4-related PD are now under consideration by the
Japanese Respiratory Association.
IgG4-related Hashimoto’s thyroiditis (IgG4-related HT)
Hashimoto’s thyroiditis (HT) has been considered a well-
deﬁned clinicopathological entity, characterized by the
presence of goiter and serum thyroid autoantibodies.
Recently, a unique subtype of HT was described, charac-
terized by the presence of prominent ﬁbrosis such as
storiform ﬁbrosis and swirling ﬁbrosis, numerous IgG4-
positive plasma cells, and elevated serum IgG4 [52], and
called IgG4-related HT [53]. Among 23 patients with HT
who underwent total thyroidectomy, 14 cases (60.8%) were
IgG4-related HT, but there were no signiﬁcant differences
in positivity for thyroid and microsome tests between
IgG4-related HT and non-IgG4 HT [54].
Riedel’s thyroiditis was ﬁrst described in 1896 in two
patients with hard goiter and tracheal compressive symp-
toms. One-third of patients with Riedel’s thyroiditis have
multifocal ﬁbrosclerosis, including sclerosing cholangitis,
salivary gland ﬁbrosis, RPF, or ﬁbrotic orbital pseudotu-
mor. Therefore, despite the lack of immunohistochemical
staining for IgG4, certain proportions of Riedel’s thyroid-
itis were considered a type of IgG4RD. Although one
patient with IgG4RD showed involvement of the lachrymal
gland and pulmonary and biliary tracts as well as Riedel’s
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roiditis is a type of IgG4RD.
IgG4-related lymphadenopathy and Castleman’s
disease
Concomitant lymphadenopathy is common in patients with
IgG4RD, and there have been several reports dealing with
the morphological and immunohistological ﬁndings of
lymph node lesions [55–57]. Although IgG4-related lym-
phadenopathy is occasionally characterized by systemic
lymphadenopathy, polyclonal hyperimmunoglobulinemia,
especially elevated IgG and IgE concentrations, and posi-
tivity for various autoantibodies, patients with IgG4RD
with generalized lymphadenopathy should only be evalu-
ated for lymphoma, sarcoidosis, multicentric Castleman’s
disease, and other malignancies.
IgG4-related lymphadenopathy can be characterized into
ﬁve histological subtypes: Castleman’s disease-like mor-
phology (type I), reactive follicular hyperplasia (type II),
interfollicular plasmacytosis and immunoblastosis (type
III), progressive transformation of germinal center-like
(type IV), and inﬂammatory pseudotumor-like morphology
(type V) [57]. In addition, IgG4-related lymphadenopathy
can be classiﬁed into two types based on the inﬁltrative
patterns of IgG4-positive cells: interfollicular plasmacytosis
(types I, II, III, and V) and intragerminal center plasmacy-
tosis (type IV). Patients with systemic IgG4-related lym-
phadenopathy were signiﬁcantly older (68.8 vs. 43.3 years)
and had signiﬁcantly lower C-reactive protein (0.29 vs.
8.71 mg/dl) and interleukin (IL)-6 (8.45 vs. 34.82 pg/ml)
concentrations than patients with multicentric Castleman’s
disease [56].
IgG4-related retroperitoneal ﬁbrosis (IgG4-related
RPF)
RPFisachronicinﬂammatoryconditionwithmarkedﬁbrosis
in retroperitoneal tissue. In patients with advanced RPF a
retroperitoneal mass covers the abdominal aorta and com-
pressestheureters,leadingtourinaryobstruction.Itsetiology
is unknown, but it has many causes, including infection,
radiation,drugs,malignanttumor,andtrauma.Three patients
with RPF and elevatedserum IgG4havebeendescribed [58],
andthehistologyofall12patientswithRPFwasreportedtobe
similar to that seen in AIP, including ﬁbrosis, intense
inﬂammatorycellinﬁltrationwithplasmacells,venulitis,and
obliterativearteritis[59].Of17patientswithRPF,10hadboth
elevatedserumIgG4andhistopathologicalfeaturestypicalof
IgG4RD, suggesting that RPF could be categorized as IgG4-
related [60]. However, in RPF, ﬁbrosis gradually progresses
during chronic inﬂammation, with lymphocyte inﬁltration
predominant during the early stages and a ﬁbroinﬂammatory
process occurring later. Therefore, determining the stage of
illness seems important for diagnosis and prediction of
response to steroid treatment [61].
IgG4-related aortitis
There have been several recent reports of inﬂammatory
aneurysms in the abdominal or thoracic aorta [62–64]. For
example, 40% of inﬂammatory abdominal aortic aneu-
rysms (AAAs) were IgG4RD, with elevated IgG4 in serum
and abundant inﬁltration of IgG4? plasma cells and
obliterative phlebitis [62]. These ﬁndings suggested that
inﬂammatory AAAs can be classiﬁed into 2 groups: IgG4-
related and IgG4-unrelated [62]. Although IgG4RD shows
good response to steroid therapy, treatment with the anti-
CD20 monoclonal antibody, rituximab, may result not only
in clinical improvement, but in the tapering or discontin-
uation of steroids or other drugs [65].
Pathogenesis and pathophysiology of IgG4RD
At present, the pathogenetic mechanism and underlying
immunological abnormalities in IgG4RD remain unclear.
The elevated serum IgG4 concentration and tissue inﬁl-
tration of IgG4-positive plasma cells are characteristic
features of IgG4RD. Because IgG4 antibodies are dynamic
molecules that can exchange Fab arms by swapping a
heavy chain and attached light chain, IgG4 can form
bi-speciﬁc antibodies, as well as functioning as a mono-
valent molecule [66, 67]. These properties may protect
against type I allergy by inhibiting IgE functions, and may
prevent type II and III allergy by blocking the Fc-mediated
effector functions of IgG1 and inhibiting the formation of
large immune complexes. The predominant expression of
IgG4 under conditions of chronic antigen exposure is
compatible with the clinical features of IgG4RD, including
its slow progression and relatively weak immune response.
Some autoantibodies, including those to pancreatic
trypsin inhibitor (PSTI), lactoferrin (LF), and carbonic
anhydrase (CA), have been detected in patients with
IgG4RD, especially in those with IgG4-related AIP [34].
Although IgG4 from the patients was able to bind the
normal epithelia of the pancreatic ducts, gallbladder, and
salivary gland ducts [68], IgG4-type autoantibodies have
not been detected in patients with IgG4RD.
Aberrant immunological ﬁndings have been observed in
patients with IgG4RD. For example, the Th2-dominant
immune response and the production of Th2-type cyto-
kines, such as IL-4, IL-5, IL-10, and IL-13, are increased
[69–71]. Furthermore, the numbers of regulatory T cells
(Treg) expressing CD4?CD25?Foxp3 are signiﬁcantly
higher in the affected tissues and peripheral blood of
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autoimmune and nonautoimmune diseases [72–74]. Over-
expression of the regulatory cytokines IL-10 and trans-
forming growth factor b (TGF-b) has also been reported in
patients with IgG4RD [74, 75]. IL-10 and TGF-b have
potent activities in directing B cells to produce IgG4 and
induce ﬁbroplasia, respectively. IL-4, IL-5, and IL-13 are
important for class switching to IgE production and
eosinophil migration. Therefore, abnormalities in the pro-
duction of these cytokines may be involved in the patho-
genesis of IgG4RD.
Perspectives on IgG4RD
Although IgG4RD is a novel clinical entity, it is not a rare
disease. Despite the effectiveness of steroid therapy, for
IgG4RD, the condition has often been misdiagnosed as a
malignant tumor, lymphoma, Sjo ¨gren’s syndrome, or other
diseases. To date, the clinical diagnostic criteria for
IgG4RD have not been established. Because IgG4RD may
occur in a variety of organs throughout the body, com-
prehensive discussions with the cooperation of many cli-
nicians from various specialized ﬁelds is needed to
establish uniform diagnostic criteria. At present, the diag-
nostic criteria for IgG4-MD (Table 2)[ 8] and those for
IgG4-AIP type 1 (Table 5)[ 14] have been established.
Consensus has been reached on two diagnostic criteria
for IgG4RD: (1) serum IgG4 concentration [135 mg/dl,
and (2) [40% of IgG-positive plasma cells being IgG4-
positive. The MHLW Japan team has proposed guidelines
for the diagnosis of IgG4RD; these are shown in Table 3.
The formulation of organ-speciﬁc (i.e., kidney and pul-
monary) diagnostic criteria for IgG4RD requires coopera-
tion with the relevant societies. Although IgG4RD
responds well to steroid therapy, recurrence and relapse
occur following the early reduction or withdrawal of
prednisone. Therefore, it is necessary to develop treatment
guidelines to establish initial doses of steroids, tapering
procedures, and maintenance doses. The MHLW Japan
team is currently pursuing a ‘‘Prospective study for creat-
ing IgG4-related disease treatment guidelines’’, and uniﬁed
clinical guidelines are expected in the near future.
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